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PKD-mediated phosphorylation of class IIa HDACs frees the MEF2 transcription factor to activate
genes that govern muscle differentiation and growth. Studies of the regulation and function of this
signaling axis have involved MC1568 and Gö-6976, which are small molecule inhibitors of class IIa
HDAC and PKD catalytic activity, respectively. We describe unanticipated effects of these com-
pounds. MC1568 failed to inhibit class IIa HDAC catalytic activity in vitro, and exerted divergent
effects on skeletal muscle differentiation compared to a bona ﬁde inhibitor of these HDACs. In car-
diomyocytes, Gö-6976 triggered calcium signaling and activated stress-inducible kinases. Based on
these ﬁndings, caution is warranted when employing MC1568 and Gö-6976 as pharmacological tool
compounds to assess functions of class IIa HDACs and PKD.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction which includes CaM kinase II and protein kinase D (PKD) [11–The 18 mammalian histone deacetylases (HDACs) are grouped
into four classes (I, II, III and IV) [1]. Class II HDACs are further
divided into two subclasses, IIa (HDACs 4, 5, 7 and 9) and IIb
(HDACs 6 and 10). Class IIa HDACs serve critical roles in the control
of muscle gene expression [2]. These HDACs have long (500
amino acid) amino-terminal extensions that harbor binding sites
for pro-myogenic transcription factors such as myocyte enhancer
factor 2 (MEF2) [3–7]. In skeletal muscle cells, binding of class IIa
HDACs to MEF2 results in suppression of MEF2 target genes that
govern differentiation of myoblasts into multi-nucleated myotubes
[8,9]. In cardiac muscle, interaction of class II HDACs with MEF2
blocks hypertrophic growth of the heart [10].
The amino-terminal extensions of class IIa HDACs also harbor
two serine residues that confer signal-responsiveness to the
enzymes. These sites are phosphorylated by members of the
calcium/calmodulin-dependent kinase (CaM kinase) superfamily,14]. Phosphorylation of class IIa HDACs creates docking sites for
the 14-3-3 chaperone protein, which promotes nuclear export of
the transcriptional repressors. Thus, in response to CaMK/PKD sig-
naling, class IIa HDACs dissociate fromMEF2, freeing the transcrip-
tion factor to activate downstream target genes. The identiﬁcation
of PKD as a class IIa HDAC kinase was aided by the use of a
pharmacological tool compound, Gö-6976 [15], which functions
as an ATP-competitive inhibitor of the three PKD isoforms, PKD-
1, -2 and -3 [16].
Despite having conserved catalytic domains, class IIa HDACs are
unable to deacetylate histones [17]. In fact, bona ﬁde substrates of
class IIa HDACs have yet to be identiﬁed, and class IIa HDAC cat-
alytic activity can only be monitored using an artiﬁcial substrate
[18]. Class IIa HDAC catalytic activity is largely resistant to com-
monly used HDAC inhibitors, such as suberanilohydroxamic acid
(SAHA) [19]. Several years ago, MC1568 (originally referred to as
compound 2f) was described as the ﬁrst class IIa HDAC-selective
inhibitor [20]. MC1568 has been used in a multitude of studies
as a chemical biological probe to assess the function of class IIa
HDAC catalytic activity in various physiological and pathophysio-
logical processes. For example, MC1568 was recently found to
block pulmonary artery endothelial cell proliferation and rescue
experimental pulmonary hypertension [21], as well as block hep-
atic stellate cell activation and liver ﬁbrosis in mice [22].
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ferentiation by stabilizing MEF2:HDAC4 complexes and preventing
MEF2 acetylation [23].
In the current studies, we conﬁrm that MC1568 blocks dif-
ferentiation of C2C12 myoblasts into multinucleate myotubes.
However, the anti-myogenic activity of this compound appears to
be due to off-target action(s), since enzymatic assays revealed an
inability of MC1568 to inhibit class IIa HDAC catalytic activity.
Furthermore, we validate that Gö-6976 is a PKD inhibitor.
Surprisingly, however, exposure of primary cardiomyocytes to
Gö-6976 leads to enhanced calcium signaling and activation of
stress-inducible kinases such as p38 mitogen-activated protein
kinase and c-Jun N-terminal kinase (JNK). These ﬁndings highlight
the need to employ multiple, structurally distinct compounds
when assessing the functions of class IIa HDACs and PKD using
pharmacological tools.
2. Materials and methods
2.1. Inhibitors, antibodies and adenoviruses
Gö-6976 was obtained from EMD Millipore and A.G. Scientiﬁc.
MC1568 was purchased from both Sigma–Aldrich and Selleck
Chemicals. SAHA, MGCD0103 and Tubastatin A were purchased
from Selleck Chemicals, whereas diphenylacetohydroxamic acid
(DPAH) [24] was obtained from Sigma–Aldrich (D6071). DPAH
was also synthesized in-house, and its purity was conﬁrmed to
be greater than 95%. U-73122 was procured from Tocris
Bioscience. For all studies, DMSO was used as the compound vehi-
cle (ﬁnal DMSO concentration = 0.1%). For immunoblotting, cells
were homogenized in PBS (pH 7.4) containing 0.5% Triton X-100,
300 mM NaCl and protease/phosphatase inhibitor cocktail
(Thermo Fisher) using a Bullet Blender homogenizer (Next
Advance). The following. Homogenates were sonicated and clari-
ﬁed by centrifugation at 12000  g for 10 minutes. Antibodies
were used for immunoblotting: anti-calnexin (Santa Cruz
Biotechnology; sc-11397), anti-PKD1 (Cell Signaling Technology;
#2052), anti-phospho-PKD1 Ser-738/742 (Cell Signaling
Technology; #2054), anti-phospho-PKD1 Ser-910 (Cell Signaling
Technology; #2051), anti-phospho-ERK1/2 (Cell Signaling
Technology; 4370), anti-phospho-p38 (Cell Signaling Technology;
4631) and anti-phospho-JNK (Cell Signaling Technology; 4668).
Adenoviruses for wild-type PKD1 and catalytically inactive PKD1
harboring a K612W substitution (K/W) [25] were generated using
pShuttle-CMV, as previously described [26].
2.2. Primary cardiac myocyte preparation
Neonatal rat ventricular myocytes (NRVMs) were prepared
from hearts of 1- to 3-day-old Sprague–Dawley rats, as previously
described [27]. Cells were cultured overnight on 10-cm plates
coated with gelatin (0.2%; Sigma–Aldrich) in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing calf serum (10%), L-glutamine
(2 mM), and penicillin–streptomycin. After overnight culture, cells
were washed with serum-free medium and maintained in DMEM
supplemented with L-glutamine, penicillin–streptomycin, and
Neutridoma-SP (0.1%; Roche Applied Science), which contains
albumin, insulin, transferrin, and other deﬁned organic and inor-
ganic compounds. Adult rat ventricular myocytes (ARVMs) were
obtained from female Sprague–Dawley rats, as described pre-
viously [28]. ARVMs were plated at a density of 100–150 cells/
mm2 on laminin-coated 60-mm plates and maintained in serum-
free DMEM supplemented with albumin (2 mg/mL), 2,3-butane-
dione monoxime (1 mg/mL), L-carnitine (2 mM), creatine (5 mM),
penicillin–streptomycin (100 lg/mL), triiodothyronine (1 pM),
and taurine (5 mM).2.3. C2C12 culture and transfection
C2C12 myoblasts were obtained from ATCC and were main-
tained in DMEM containing 10% FBS, L-glutamine (2 mM), and
penicillin–streptomycin. C2C12 cells were induced to differentiate
by replacing FBS in the culture medium with 2% horse serum.
C2C12 cells were transfected with a 3 MEF2-luciferase plasmid,
which contains three tandem copies of the mouse muscle creatine
kinase enhancer MEF2 site upstream of the thymidine kinase pro-
moter [29], using FuGENE 6 (Promega). To control for non-speciﬁc
effects of compounds on luciferase expression, parallel plates of
C2C12 cells were transfected with a TATA-luciferase plasmid lack-
ing MEF2 binding sites. Luciferase activity is expressed as a ratio of
MEF2-luciferase:TATA-luciferase.
2.4. In vitro kinase assays
NRVMs on 10-cm plates (2 106 cells/plate) were serum starved
for 4 h and subsequently exposed to phenylephrine (10 lM) for 1 h.
Following treatment, total protein lysates were prepared, as
described above for immunoblotting. Total protein (200 lg) was
incubated in buffer (500 ll) containing antibodies speciﬁc for PKD1
(Santa Cruz Biotechnology; sc-639), PKD2 (Bethyl Laboratories;
BL844) or PKD3 (Bethyl Laboratories; BL1282), overnight at 4 Cwith
rocking. Antibody-protein complexes were captured with Protein G-
Sepharose beads (GE Healthcare Life Sciences), with incubation for
1 h at 4 C. Immunoprecipitateswere equilibratedwith kinase buffer
(20 mM HEPES, pH 7.5, 20 mM MgCl2), and kinase reactions were
initiated upon addition of ATP (0.1 mM), 10 lCi [c-32P]-ATP, and
2 lg Syntide-2 substrate (Anaspec). Kinase reactions were carried
out at 30 C for 30 min, and terminated with 2 SDS–PAGE loading
dye. Phospho-Syntide-2 peptide was resolved by SDS–PAGE and
visualized by autoradiography.
2.5. Calcium measurements
NRVMs were loaded with 5 lM Fluo 3-AM and 0.05% pluronic
acid (both from Invitrogen) dissolved in Tyrode’s solution (in
mM: 140 NaCI, 5 KCl, 1 MgCl2, 1 CaCl2, 10 HEPES, 5 Glucose, pH
adjusted to 7.4 with NaOH) for 20 min. NRVMs were then washed
three times in Tyrode’s solution with gentle agitation. After a
10 min de-esteriﬁcation period, Fluo-3 AM-loaded cells, bathed in
Tyrode’s solution, were placed on the stage of an LSM 510 META
scanning laser confocal microscope, and viewed with a Zeiss Plan-
Neoﬂuar 40 objective (Zeiss). Fluo-3 AM was excited with the
488-nm line of an argon laser (30-mWmaximum output, operated
at 50% or 6.3A, attenuated to 5%). The emitted ﬂuorescence was
directed through a dual 488/543 dichroic mirror to a photomulti-
plier equipped with a 505 nm long-pass ﬁlter. Caffeine (Sigma–
Aldrich) or Gö-6976 (Sigma–Aldrich) were diluted to working con-
centrations (5 mM and 1 lM, respectively) in Tyrode’s solution, and
were delivered via a manually-operated, gravity-driven global per-
fusion system. Spontaneous Ca2+ ﬂuctuations were analyzed qual-
itatively using NIH Image J software. Fluorescence amplitude data
are expressed as DF/F, where F represents baseline ﬂuorescence
prior to application of caffeine or Gö-6976, and DF represents the
change in peak ﬂuorescence during the application of either com-
pound. All Ca2+ imaging experiments were performed at room tem-
perature (25 C) in the University of Colorado Denver Advanced
Light Microscopy Core.
2.6. Immunostaining
Following experimental treatments, NRVMs were washed twice
in PBS (pH 7.4), ﬁxed with formalin (10%) in PBS, permeabilized
and blocked with PBS containing NP-40 (0.1%) and bovine serum
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taining primary antibody speciﬁc for PKD1 phosphorylated on ser-
ine-916 (1:1000 dilution; Cell Signaling Technology; #2051)
overnight at 4 C. Cells were washed four times in PBS and incu-
bated in PBS-NP-40-BSA containing a Cy3-conjugated secondary
antibody (1:200 dilution; Jackson Laboratories) for 30 min at room
temperature. Cells were washed four times in PBS and then
covered with mounting solution (SlowFade; Molecular Probes)
and glass coverslips. For myosin staining of skeletal muscle cells,
immunohistochemical analysis was performed using an anti-sar-
comeric myosin (MF20; Iowa Hybridoma Bank) primary antibody,
a secondary antibody (biotinylated anti-mouse IgG; Vector Labs),
and Elite ABC and VECTOR NovaRED Substrate Kits (Vector Labs).
The percentage of the plate containing myosin-positive myotubes
was quantiﬁed in a blinded manner using an Axiovert 200 inverted
microscope with a digital camera equipped with AxioVision imag-
ing software (Zeiss). Values were averaged from ﬁve independent
plates of cells per condition.
2.7. HDAC activity assays
HDAC activity assays were completed as previously reported
[30]. Each HDAC substrate was based on e-N-acylated lysine,
derivatized on the carboxyl group with amino-methylcoumarin
(AMC) [18]. Subsequent to deacylation by HDACs, trypsin was used
to release AMC, resulting in a signiﬁcant increase in ﬂuorescence.
Rat heart homogenates were employed as a source of HDAC activ-
ity. Homogenates were prepared in PBS (pH 7.4) containing 0.5%
Triton X-100, 300 mM NaCl and protease/phosphatase inhibitor
cocktail (Thermo Fisher), using a Bullet Blender homogenizer
(Next Advance). Tissue extracts were diluted into PBS in 100 ll
total volume in a 96-well plate (60 lg ventricular protein/well).
Tissue extracts were incubated with increasing concentrations of
HDAC inhibitors for 1 h. Substrates were added (5 ll of 1 mM
DMSO stock solutions), and the plates were placed at 37 C for
2–3 h. Finally, developer/stop solution was added (50 ll per well
of PBS with 1.5% Triton X-100, 3 lM TSA, and 0.75 mg/mL trypsin),
followed by an additional 20 min incubation at 37 C. AMC ﬂuores-
cence was measured using a BioTek Synergy 2 plate reader, with
excitation and emission ﬁlters of 360 nm and 460 nm, respectively
(each with 40 nm bandwidth), along with a 400 nm dichroic top
mirror. As a control, HDAC inhibitors were incubated with AMC
without the appended substrate. The importance of this step is
illustrated by the fact that MC1568 quenches AMC-generated ﬂuo-
rescence (sFig. 1). Background signals from buffer blanks were sub-
tracted, and the data were normalized to appropriate controls. To
monitor recombinant HDAC4 activity, 15 ng of recombinant
human HDAC4 (BPS Bioscience; #50004) or PBS blank was added
to a 96-well plate. Wells were incubated for 1 h with increasing
concentrations of DPAH or MC1568 (Sigma–Aldrich), prior to addi-
tion of the cell-permeable class IIa ﬂuorescent HDAC substrate.
After two hours, stop buffer was added to each well and incubated
for 20 min at 37 C, and deacetylase activity was quantiﬁed as
described above.
3. Results
3.1. Differential effects of class IIa HDAC inhibitors on skeletal muscle
differentiation
Association of MEF2 with class IIa HDACs leads to repression of
downstream target genes that promote skeletal muscle differentia-
tion (Fig. 1A). When class IIa HDACs are phosphorylated by kinases
such as PKD, these HDACs are exported to the cytoplasm, and MEF2
becomes transcriptionally active. Gö-6976 inhibits the catalyticactivity of PKD, while MC1568 and DPAH are small molecule inhi-
bitors of class IIa HDAC catalytic activity (Fig. 1A and B).
To assess the impact of isoform-selective HDAC inhibition on
skeletal muscle differentiation, C2C12 myoblasts were differenti-
ated in the absence or presence SAHA (pan-HDAC inhibitor),
MGCD0103 (class I HDAC inhibitor), Tubastatin A (HDAC6 inhibi-
tor), MC1568 or DPAH. Pre-treatment with SAHA and MGCD0103
led to complete inhibition of C2C12 cell differentiation, as indi-
cated by the absence of myosin-positive myotubes in these cul-
tures (Fig. 1C). Consistent with prior ﬁndings, HDAC6 inhibition
with Tubastatin A moderately impaired myogenesis [31], while
the class IIa HDAC inhibitor MC1568 completely abolished forma-
tion of multinucleated myotubes [23]. Surprisingly, however, the
structurally distinct class IIa HDAC inhibitor, DPAH, failed to block
differentiation of C2C12 cells. Higher magniﬁcation images of cells
from a second experiment with MC1568 and DPAH revealed that
DPAH actually enhanced C2C12 myotube formation
(Fig. 1D and E). The differential actions of the two compounds on
muscle differentiation correlated with their effects on MEF2 tran-
scriptional activity (Fig. 1F), with MC1568 and DPAH repressing
and stimulating a MEF2-dependent reporter gene, respectively.
3.2. Commercially available MC1568 does not inhibit class IIa HDAC
catalytic activity
To begin to address the discrepant results with MC1568 and
DPAH, the compounds were tested for their ability to block
HDAC catalytic activity in vitro. Dose-response studies were per-
formed with substrates that enable speciﬁc assessment of class I,
IIa or IIb HDAC activity. Rat left ventricular homogenates were
used as a rich source of endogenous HDACs [30]. Consistent with
prior ﬁndings [20], MC1568 had no observable effect on class I
HDAC activity (Fig. 2A). Surprisingly, however, MC1568 also failed
to inhibit class IIa HDAC activity and, instead, modestly suppressed
class IIb HDAC catalytic activity (Fig. 2B and C); HDAC6 is the pre-
dominant class IIb HDAC in these lysates [30]. In contrast, DPAH
dose-dependently inhibited class IIa HDACs (IC50 = 1.2 lM), while
having no effect on class I or IIb HDACs (Fig. 2D–F). Similar results
were obtained using independent sources of MC1568 and DPAH
(Fig. 2G–I and data not shown). To conﬁrm these ﬁndings, recom-
binant HDAC4 was used as a representative class IIa HDAC.
Consistent with the results obtained using endogenous HDACs,
MC1568 failed to block the activity of recombinant HDAC4
(Fig. 2J), while DPAH efﬁciently inhibited this class IIa HDAC
(Fig. 2K). Quantiﬁcation of class IIa HDAC activity was enabled by
the use of a substrate having a triﬂuoroacetyl group on the e-
amine, which is deacetylated by class IIa HDACs but not class I or
IIb HDACs [32].
The mechanism underlying the inability of MC1568 to inhibit
class IIa HDACs could be related to compound structure. Indeed,
nuclear magnetic resonance (NMR) data revealed the commercial
compound to be an isomer of the previously published structure
(Fig. 2L).
3.3. Gö-6976 activates stress-inducible kinases in cardiac myocytes
Among the downstream effectors of Gaq-coupled receptors in
cardiac myocytes are members of the PKD family [26,33]. The three
PKD isoforms exhibit a high degree of sequence similarity, consist-
ing of 900 amino acids, with two amino-terminal cysteine-rich
domains (CRDs), an internal pleckstrin homology domain (PH),
and carboxy-terminal catalytic domains [34,35]. PKD can be acti-
vated by protein kinase C (PKC)-mediated phosphorylation of
activation loop sites within the catalytic domain, with subsequent
auto-phosphorylation of PKD on serine-916 (Fig. 3A).
Fig. 1. Differential effects of isoform-selective HDAC inhibitors on skeletal muscle differentation. (A) A schematic representation of the PKD-class IIa HDAC axis. Gö-6976
blocks the catalytic activity of PKD, while MC1568 and DPAH inhibit the enzymatic activity of class IIa HDACs. (B) The molecular structures of the compounds used in this
study are shown. (C) C2C12 myoblasts were induced to differentiate in the absence (vehicle) or presence of the indicated HDAC inhibitors; SAHA (1 lM), MGCD0103
(500 nM), Tubastatin A (1 lM), MC1568 (10 lM) and DPAH (10 lM). After 4 days of differentiation, cells were ﬁxed and stained with an anti-myosin antibody to reveal
myosin heavy chain (MyHC)-positive skeletal myotubes. (D) C2C12 cells were induced to differentiate in the absence or presence of the class IIa HDAC inhibitors MC1568 and
DPAH, stained as described for (C), and differentiation was quantiﬁed (E); Scale bar = 10 lM. (F) C2C12 myoblasts were transfected with a MEF2-dependent luciferase
reporter gene, and the cells were subsequently induced to differentiate for three days in the absence or presence of MC1568 or DPAH. For (E) and (F), ﬁve independent plates
of cells were analyzed per condition. Numbers represent averages + S.E.M.; ⁄P < 0.05 vs. vehicle-treated cells.
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been stimulated with the a1-adrenergic receptor agonist phenyle-
phrine (PE), which potently activates PKD in cardiac myocytes.
Immunoprecipitateswere incorporated into invitrokinase reactions
containing syntide-2 substrate and [c-32P]-ATP, in the absence or
presence of Gö-6976. As shown in Fig. 3B, Gö-6976 effectively inhib-
ited theabilityof PKD1, -2and-3 tophosphorylate the synthetic sub-
strate, and also blocked auto-phosphorylation of PKD1 and PKD3;
PKD2 auto-phosphorylation was not detected in the assay.
Next, the impact of Gö-6976 on auto-phosphorylation of PKD1
on serine-916 in intact, unstimulated cardiomyocytes was
assessed. Paradoxically, treatment of NRVMs with this compoundled to enhanced serine-916 phosphorylation, while a related com-
pound, Gö-6983, which targets PKC but not PKD, had no effect on
PKD1 phosphorylation (Fig. 3C). Stimulation of PKD1 serine-916
phosphorylation by Gö-6976 in NRVMs was conﬁrmed by
immunoblotting, and was shown to occur with compounds
obtained from two independent vendors (Fig. 3D; left-hand
panels). Gö-6976 similarly promoted phosphorylation of the
activation loop sites on PKD1 (serines-744 and -748) in NRVMs.
Furthermore, Gö-6976 was also able to increase PKD1 phos-
phorylation in adult rat ventricular myocytes (ARVMs) (Fig. 3D;
right-hand panels), but not in HEK293 ﬁbroblasts (Fig. 3E), sug-
gesting cell type-speciﬁcity of the effects.
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Fig. 2. MC1568 does not block class IIa HDAC catalytic activity. Dose-response studies were performed to assess the ability of MC1568 and DPAH to inhibit HDAC catalytic
activity in vitro. (A–C) MC1568 (from Sigma–Aldrich) failed to inhibit class I and class IIa HDAC activity, but did block class IIb activity at higher concentrations. (D–F) DPAH
dose-dependently, and selectively, inhibited class IIa HDAC catalytic activity. MC1568 from Selleck Chemicals also failed to inhibit endogenous class IIa HDAC activity (G–I).
MC1568 was unable to inhibit the catalytic activity of a recombinant form of a prototypical class IIa HDAC, HDAC4, while DPAH efﬁciently inhibited recombinant HDAC4 (J
and K). (L) Analysis of NMR data from Sigma and Selleck revealed the commercial MC1568 to be a 2,5-disubstituted pyrrole, as opposed to the 2,4-disubstituted isomer shown
in Fig. 1B.
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paradoxical, since serine-916 is thought to be an auto-phos-
phorylation site, and Gö-6976 is an ATP-competitive inhibitor of
PKD [16]. To determine if Gö-6976 triggers PKD auto-phosphoryla-
tion, experiments were performed with ectopic PKD1 expressed in
NRVMs via adenoviruses. Consistent with the results with endoge-
nous PKD1, ectopically expressed wild-type PKD1 was efﬁciently
phosphorylated on serine-916 upon treatment with PE or Gö-
6976 (Fig. 3F). When normalized to total PKD1 expression, ser-
ine-916 phosphorylation of catalytically inactive PKD1 (K/W) was
attenuated in PE-treated cells (Fig. 3F, lane 5), consistent witha1-adrenergic receptor signaling causing PKD1 auto-phosphoryla-
tion [26,33]. Remarkably, however, serine-916 of PKD1 (K/W)
was still phosphorylated following treatment with Gö-6976
(Fig. 3F, lane 6), suggesting that the compound stimulates PKD1
serine-916 phosphorylation through a PKD-independent mecha-
nism governed by a distinct kinase(s). This explains how Gö-
6976 can inhibit PKD catalytic activity (Fig. 3B), and still trigger
PKD Ser-916 phosphorylation. Additional immunoblotting studies
revealed that Gö-6976 also stimulated phosphorylation of the
stress-inducible MAP kinases p38 and JNK in cardiomyocytes, but
not extracellular signal-regulated kinase (ERK1/2) (Fig. 3G).
Fig. 3. Gö-6976 activates stress-dependent kinases in cardiomyocytes. (A) Schematic representation of PKD1, with cysteine-rich domains (CRD) and a pleckstrin homology
(PH) domain indicated. PKC phosphorylates activation loop sites in the catalytic domain of PKD1 (serines-744 and -748), resulting in stimulation of the kinase. Serine-916 can
undergo auto-phosphorylation. (B) NRVMs were stimulated with phenylephrine (PE; 10 lM) for 1 h. Whole cell lysates were immunoprecipitated (IP) with antibodies to
PKD1, -2 or -3 and incorporated into in vitro kinase reactions in the absence or presence of Gö-6976 (10 lM). Gö-6976 inhibited the ability of each PKD isoform to
phosphorylate the synthetic syntide substrate, and blocked auto-phosphorylation of PKD1 and PKD3. (C) NRVMs were treated with Gö-6976 (10 lM) or Gö-6983 (10 lM) for
1 h, and PKD serine-916 phosphorylation was assessed by indirect immunoﬂuorescence. Scale bar = 10 lM. (D) NRVMs (left panel) or adult rat ventricular myocytes (right
panel) were treated for 1 h with vehicle control or Gö-6976 (10 lM) from two independent commercial sources, as described in the Section 2. Protein homogenates were
immunoblotted with antibodies to the indicated forms of PKD1. (E) HEK293A ﬁbroblasts were treated for 1 h with Gö-6976 (10 lM) or phorbol-12-myristate-13-acetate
(PMA; 50 nM), which served as a positive control for PKC and PKD activation. Immunblotting was performed as in (D). (F) NRVMs were infected with adenoviruses encoding
wild-type PKD1 or PKD1K/W, which is catalytically inactive. Cells were treated for 1 h with PE (10 lM) or Gö-6976 (10 lM), lysed, and immunoblotted with the indicated
antibodies. (G) NRVMs were treated for 1 h with Gö-6976 (10 lM) from two different vendors, and protein homogenates were immunoblotted with antibodies to the
indicated proteins.
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Given the ability of Gö-6976 to activate multiple kinases (PKC,
p38 and JNK) in cultured cardiomyocytes, experiments were next
performed to address the possibility that the compound functions
proximally, via a general signaling mediator(s), to stimulate
diverse downstream events. Consistent with this notion, thephospholipase C (PLC) inhibitor U-73122 blocked Gö-6976-
mediated PKD phosphorylation as efﬁciently as it blocked PE-
induced phosphorylation of the kinase (Fig. 4A). Subsequently,
effects of Gö-6976 and caffeine on calcium signaling in cardiomy-
ocytes were assessed by imaging cells that were loaded with a cal-
cium-sensitive dye, Fluo-3 AM. Spontaneous calcium transients
were detected in NRVMs prior to application of either caffeine or
1086 D.D. Lemon et al. / FEBS Letters 589 (2015) 1080–1088Gö-6976 (Fig. 4B). Caffeine treatment of NRVMs led to induction of
sarcoplasmic reticulum (SR) calcium release (Fig. 4B, top panel).
Strikingly, Gö-6976 also triggered myoplasmic calcium ﬂuctua-
tions within seconds after addition to NRVMs (Fig. 4B, bottom
panel). Effects of caffeine and Gö-6976 on NRVM calcium were dis-
tinct, with Gö-6976-induced transients having lesser amplitude
than spontaneous transients. Furthermore, Gö-6976 treatment
caused a rapid increase in myoplasmic calcium concentration,
which ultimately led to depletion of SR calcium stores.
4. Discussion
The current study demonstrates that MC1568 and Gö-6976
exert paradoxical effects when delivered to striated muscle cell15 s
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Fig. 4. Gö-6976 alters calcium signaling in cardiac myocytes. (A) NRVMs were pre-
treated with the phospholipase C (PLC) inhibitor U-73122 (1 lM) for 20 min prior to
addition of phenylephrine (PE; 10 lM) or Gö-6976 (1 or 10 lM) for 1 h.
Immunoblotting was performed to assess levels of phospho- and total PKD1. (B)
NRVMs were loaded with the calcium-sensitive dye, Fluo-3 AM. Calcium ﬂuctua-
tions prior to and after treatment with caffeine (5 mM) or Gö-6976 (1 lM) were
measured using a confocal microscope. Fluorescence amplitude data are expressed
as DF/F, where F represents baseline ﬂuorescence prior to application of caffeine or
Gö-6976, and DF represents the change in peak ﬂuorescence during the application
of either compound.cultures. Consistent with prior results, MC1568 inhibited dif-
ferentiation of C2C12 myoblasts into multinucleate myotubes.
However, this compound failed to block the enzymatic activity of
class IIa HDACs in in vitro assays. Identical ﬁndings were made
with MC1568 acquired from two different vendors. In contrast to
the data obtained with MC1568, a structurally distinct compound,
DPAH, dose-dependently inhibited class IIa HDAC catalytic activity
and enhanced, rather than inhibited, C2C12 differentiation. The
contrapositive effects of the compounds on muscle differentiation
correlated with effects on MEF2 transcriptional activity, with
MC1568 and DPAH inhibiting and activating a MEF2-driven repor-
ter gene, respectively. These results suggest that MC1568 inhibits
skeletal myogenesis through a mechanism that is independent of
suppression of class IIa HDAC catalytic activity, perhaps through
an off-target action. Furthermore, the ﬁndings with DPAH illustrate
that inhibition of class IIa HDAC catalytic activity is not sufﬁcient
to block myogenesis, as previously suggested, and, conversely,
may enhance muscle differentiation.
At least three explanations could account for our inability to
replicate the previous ﬁnding that MC1568 inhibits class IIa
HDAC catalytic activity. First, analysis of NMR spectra revealed that
commercially available MC1568 is an isomer of the published
structure. Of note, a recent medicinal chemistry report of the re-
synthesis of MC1568 deﬁned the major synthetic product to be
the same isomer sold by Sigma and Selleck [36]. As such, we cannot
rule out the possibility that the differential effects on class IIa
HDAC activity are due to distinct properties of the isomers. A sec-
ond possibility is related to the assays that were used to deﬁne
class IIa HDAC catalytic activity. We monitored catalytic activity
of the HDACs with a synthetic substrate that is speciﬁcally
deacetylated by class IIa HDACs; this substrate is not deacetylated
by other HDAC isoforms. In contrast, Mai et al. used a histone
H4-3H-acetyl-peptide substrate [20]. However, it should be noted
that follow-up studies by Mai and others did employ the same
AMC-based ﬂuorescent class IIa substrate used in our work [23],
and we have found that the AMC ﬂuorophore is non-speciﬁcally
quenched by MC1568 (sFig. 1). Thus, a third explanation for our
disparate ﬁndings is that MC1568 creates a false positive reading
by quenching AMC-generated ﬂuorescence of non-histone syn-
thetic substrates. We circumvented this issue by normalizing the
signal obtained upon addition of MC1568 to AMC-class IIa HDAC
substrate to the signal obtained with AMC alone (Fig. 2B, H and
J; see Materials and methods).
We also show that the staurosporine analog, Gö-6976, stimu-
lates stress-dependent kinases in culture neonatal and adult car-
diac myocytes, but not in ﬁbroblasts. This surprising action of
Gö-6976 is blocked by U-73122, which is a PLC inhibitor.
Furthermore, we show that Gö-6976 alters calcium signaling in
NRVMs within seconds after treatment. These ﬁndings suggest
the possibility that Gö-6976 has an off-target action that serves
to activate a cell surface receptor(s) to stimulate PLC-mediated cal-
cium release (Fig. 4C).
Activation of cardiac stress signaling by Gö-6976 was initially
indicated by induction of PKD phosphorylation on serine-916,
which is unexpected since this is an auto-phosphorylation site,
and Gö-6976 is an ATP-competitive inhibitor of PKD [16]. In this
regard, it is important to stress the distinction between auto-phos-
phorylation of PKD and phosphorylation of downstream substrates
by PKD. Rybin et al. showed that PKD1 serine-916 auto-phos-
phorylation does not correlate with the ability of the kinase to
phosphorylate downstream substrates such as CREB [37].
Furthermore, several studies have shown that PKD-mediated phos-
phorylation of HDAC5 can be blocked under conditions where ser-
ine-916 phosphorylation persists [15,26,38]. Our results with
catalytically inactive PKD1 (Fig. 3F) suggest that another kinase(s)
is phosphorylating serine-916 in Gö-6976-treated cells.
D.D. Lemon et al. / FEBS Letters 589 (2015) 1080–1088 1087Chemical biological probes have the potential to provide key
insights into the roles of speciﬁc targets in the control of various
biological processes and disease pathways. Ideally, results should
be conﬁrmed with at least two independent, structurally distinct
compounds that target the same protein, thereby reducing the
possibility that observed effects are governed by ‘‘off-target’’
actions of a given small molecule. In this regard, several novel
and highly selectively small molecule inhibitors of class IIa
HDACs and PKD have recently been described [24,38–46]. These
powerful pharmacological tools should help clarify the roles of
class IIa HDAC and PKD catalytic activity in striated muscle cell dif-
ferentiation and growth.
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